CA2798441A1 - Methods for predicting sensitivity to treatment with a targeted tyrosine kinase inhibitor - Google Patents

Methods for predicting sensitivity to treatment with a targeted tyrosine kinase inhibitor Download PDF

Info

Publication number
CA2798441A1
CA2798441A1 CA2798441A CA2798441A CA2798441A1 CA 2798441 A1 CA2798441 A1 CA 2798441A1 CA 2798441 A CA2798441 A CA 2798441A CA 2798441 A CA2798441 A CA 2798441A CA 2798441 A1 CA2798441 A1 CA 2798441A1
Authority
CA
Canada
Prior art keywords
level
sample
subject
marker
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2798441A
Other languages
French (fr)
Inventor
Evelyn M. Mckeegan
Peter Ansell
Barry L. Dowell
Ke Zhang
Viswanath Devanarayan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Original Assignee
AbbVie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AbbVie Inc filed Critical AbbVie Inc
Publication of CA2798441A1 publication Critical patent/CA2798441A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Methods and kits for predicting the sensitivity of a cancer to treatment with a targeted tyrosine kinase inhibitor are disclosed.

Claims (60)

1. A method for predicting the sensitivity of a cancer in a subject to administration of ABT-869 to the subject, the method comprising the step of:

determining in a sample obtained from the subject a level of at least one marker selected from the group consisting of: neuron specific enolase (NSE), cancer antigen 125 (CA125), CYFRA 21-1 and carcinoma embryonic antigen (CEA), wherein any one of:
a level of NSE below a predetermined level for NSE, a level of CYFRA 21-1 below a predetermined level for CYFRA 21-1, a level of CA125 below a predetermined level for CA125, a level of CEA
above a predetermined level for CEA, or any combination thereof, indicates increased sensitivity of the subject's cancer to the administration of ABT-869 relative to a subject with a level of NSE, CA125 or CYFRA 21-1 above the predetermined level for each marker, or to a subject with a level of CEA below the predetermined level for each marker.
2. The method according to claim 1, wherein the cancer is non small-cell lung cancer.
3. The method according to claim 1, wherein the sample is a blood sample.
4. The method according to claim 1, wherein the sample is a serum or a plasma sample.
5. The method according to claim 1, wherein the method further comprises obtaining the sample from the subject.
6. The method according to claim 1, wherein the level of each marker is determined by immunohistochemistry or immunoassay.
7. The method according to claim 1, comprising determining the levels of at least two markers selected from the group consisting of: NSE, CYFRA 21-1, CA 125 and CEA.
8. The method according to claim 1, comprising determining the levels of NSE, CA125, CYFRA 21-1 and CEA.
9. The method according to claim 7 or 8, wherein the method further comprises generating a marker signature for the subject from the levels of the two or more markers, wherein a marker signature having a predetermined pattern indicates an increased sensitivity of the subject to administration of ABT-869, relative to a marker signature lacking the predetermined pattern.
10. The method according to claim 7 or 8, wherein the method further comprises comparing the levels of the two or more markers in the sample with levels of the same markers in a control sample by applying a classification tree analysis.
11. The method according to claim 10, wherein the classification tree analysis is performed by a computer process.
12. A method of predicting the sensitivity of a cancer in a subject to administration of ABT-869, the method comprising the step of:

determining in a sample obtained from the subject levels of markers in a marker panel comprising NSE, CA 125, CYFRA 21-1 and CEA, and comparing the level of each marker in the sample to a predetermined level for each marker, wherein the level of each marker in the sample relative to the predetermined level for each marker indicates sensitivity of the cancer to administration of ABT-869 to the subject.
13. The method according to claim 12, wherein comparing the level of each marker in the sample to a predetermined level for each marker comprises comparing the marker levels to a level of each of the markers in a reference sample, wherein the reference sample contains each of the markers at a level corresponding to the predetermined level for each marker.
14. The method according to claim 12, wherein the cancer is non small-cell lung cancer.
15. The method according to claim 12, wherein the NSE level in the subject's sample is below the predetermined level for NSE.
16. The method according to claim 12, wherein the CYFRA 21-1 level in the subject's sample is below the predetermined level for CYFRA 21-1.
17. The method according to claim 12, wherein the CEA level in the subject's sample is above the predetermined level for CEA.
18. The method according to claim 12, wherein the CA125 level in the subject's sample is below the predetermined level for CA125.
19. The method according to claim 12, wherein the sample from the subject is a blood sample.
20. The method according to claim 12, wherein the sample from the subject is a serum or a plasma sample.
21. The method according to claim 12, wherein the method further comprises obtaining the sample from the subject.
22. The method according to claim 12, wherein the level of each marker in the subject's sample is determined by immunohistochemistry or immunoassay.
23. The method of claim 12, wherein the method further comprises generating a marker signature for the subject from the levels of the markers, wherein a marker signature having a predetermined pattern indicates an increased sensitivity of the subject to administration of ABT-869, relative to a subject having a marker signature lacking the predetermined pattern.
24. The method of claim 12, wherein the method further comprises comparing the levels of the markers in the subject's sample with levels of the markers in the reference sample by applying a classification tree analysis.
25. The method of claim 24, wherein the classification tree analysis is performed by a computer process.
26. A method for classifying one or more subjects each having or suspected of having a cancer, for predicted efficacy of administration of ABT-869 for the treatment of the cancer, the method comprising determining in a sample from each subject, the level of at least one marker selected from the group consisting of: NSE, CA125, CYFRA 21-1 and CEA, wherein any one of-a reduced level of NSE relative to the level of NSE in a reference sample, a reduced level of CYFRA 21-1 relative to the level of CYFRA21-1 in the reference sample, an elevated level of CEA relative to the level CEA in the reference sample, a reduced level of CA125 relative to the level CA125 in the reference sample or any combination thereof, indicates sensitivity of the cancer to administration of ABT-869 to the subject.
27. The method according to claim 26, wherein the method further comprises classifying each subject as being sensitive to treatment with ABT-869 based on the level of at least one of NSE, CYFRA 21-1, CA125 and CEA.
28. The method according to claim 26, wherein the subject or subjects have or are suspected of having non small-cell lung cancer.
29. The method according to claim 26, wherein the NSE level in the subject's sample is reduced relative to the level of NSE in the reference sample.
30. The method according to claim 26, wherein the CYFRA 21-1 level in the subject's sample is reduced relative to the level of CYFRA 21-1 in the reference sample.
31. The method according to claim 26, wherein the CEA level in the subject's sample is elevated relative to the level of CEA in the reference sample.
32. The method according to claim 26, wherein the CA125 level in the subject's sample is reduced relative to the level of CA125 in the reference sample.
33. The method according to claim 26, wherein the sample is a blood sample.
34. The method according to claim 26, wherein the sample is a serum or a plasma sample.
35. The method according to claim 26, wherein the method further comprises obtaining the sample from each subject.
36. The method according to claim 26, wherein the level of each marker is determined by immunohistochemistry or immunoassay.
37. The method according to claim 26, wherein the method further comprises generating a marker signature for each subject from the levels of the one or more markers, wherein a marker signature having a predetermined pattern indicates an increased sensitivity of the subject to administration of ABT-869, relative to a subject having a marker signature lacking the predetermined pattern.
38. The method according to claim 26, wherein the method further comprises comparing the levels of the markers in each subject's sample with levels of the same markers in the reference sample by applying a classification tree analysis.
39. A kit for predicting the sensitivity of a cancer in a subject to administration of ABT-869 to the subject, comprising:

a. an array comprising one or more binding reagents, each binding reagent having independent binding specificity for at least one marker selected from the group consisting of NSE, CYFRA 21-1, CA125 and CEA, wherein each binding reagent is independently bound to a discrete location on at least one substrate; and b. a control sample containing a predetermined level of the marker or markers in the array, wherein the predetermined level for each marker is a level relative to which a level for that marker indicates a sensitivity of the subject's cancer to the administration of ABT-869.
40. The kit according to claim 39, wherein the cancer is non small-cell lung cancer.
41. The kit according to claim 39, wherein the level of NSE in the control sample is a level below which a level of NSE in a subject's sample is indicative of sensitivity of the subject's cancer to the administration of ABT-869.
42. The kit according to claim 39, wherein the level of CYFRA 21-1 in the control sample is a level below which a level of CYFRA 21-1 in a subject's sample is indicative of sensitivity of the subject's cancer to the administration of ABT-869.
43. The kit according to claim 39, wherein the level of CA125 in the control sample is a level below which a level of CA125 in a subject's sample is indicative of sensitivity of the subject's cancer to the administration of ABT-869.
44. The kit according to claim 39, wherein the level of CEA in the control sample is a level above which a level of CEA in a subject's sample is indicative of sensitivity of the subject's cancer to the administration of ABT-869
45. The kit according to claim 39, wherein the one or more substrates each comprise a solid support coupled to a detectable label.
46. The kit according to claim 45, wherein the detectable label comprises a fluorescent compound.
47. The kit according to claim 39, further comprising instructions for determining the level of each marker in a sample from the subject.
48. The kit according to claim 47, wherein the sample from the subject is a blood sample.
49. The kit according to claim 47, wherein the sample from the subject is a plasma sample.
50. The kit according to claim 47, wherein the sample from the subject is a serum sample.
51. A kit for predicting the sensitivity of a cancer in a subject to administration of ABT-869 to the subject, comprising:

a. a microarray of markers comprising one or more selected from the group consisting of NSE, CYFRA 21-1, CA125, CEA and truncated forms thereof, and b. a control sample containing a predetermined level of the marker or markers, wherein the predetermined level for each marker is a level relative to which a level for that marker indicates a sensitivity of the subject's cancer to the administration of ABT-869.
52. The kit according to claim 51, wherein the cancer is non small-cell lung cancer.
53. The kit according to claim 51, wherein the level of NSE in the control sample is a level below which a level of NSE in a subject's sample is indicative of sensitivity of the subject's cancer to the administration of ABT-869.
54. The kit according to claim 51, wherein the level of CYFRA 21-1 in the control sample is a level below which a level of CYFRA 21-1 in a subject's sample is indicative of sensitivity of the subject's cancer to the administration of ABT-869.
55. The kit according to claim 51, wherein the level of CA125 in the control sample is a level below which a level of CA125 in a subject's sample is indicative of sensitivity of the subject's cancer to the administration of ABT-869.
56. The kit according to claim 51, wherein the level of CEA in the control sample is a level above which a level of CEA in a subject's sample is indicative of sensitivity of the subject's cancer to the administration of ABT-869
57. The kit according to claim 51, further comprising instructions for determining the level of each marker in a sample from the subject.
58. The kit according to claim 51, wherein the sample from the subject is a blood sample.
59. The kit according to claim 51, wherein the sample from the subject is a plasma sample.
60. The kit according to claim 51, wherein the sample from the subject is a serum sample.
CA2798441A 2010-05-07 2011-05-04 Methods for predicting sensitivity to treatment with a targeted tyrosine kinase inhibitor Abandoned CA2798441A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33254510P 2010-05-07 2010-05-07
US61/332,545 2010-05-07
PCT/US2011/035213 WO2011140234A1 (en) 2010-05-07 2011-05-04 Methods for predicting sensitivity to treatment with a targeted tyrosine kinase inhibitor

Publications (1)

Publication Number Publication Date
CA2798441A1 true CA2798441A1 (en) 2011-11-10

Family

ID=44121156

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2798441A Abandoned CA2798441A1 (en) 2010-05-07 2011-05-04 Methods for predicting sensitivity to treatment with a targeted tyrosine kinase inhibitor

Country Status (6)

Country Link
EP (1) EP2567232A1 (en)
JP (1) JP2013525814A (en)
CN (1) CN103038638A (en)
CA (1) CA2798441A1 (en)
MX (1) MX2012012986A (en)
WO (1) WO2011140234A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120190563A1 (en) * 2010-05-07 2012-07-26 Abbott Laboratories Methods for predicting sensitivity to treatment with a targeted tyrosine kinase inhibitor
CN108369234B (en) * 2015-10-23 2020-12-01 豪夫迈·罗氏有限公司 Methods of identifying individuals to be treated by chemotherapy based on marker molecules and related uses
WO2018148600A1 (en) * 2017-02-09 2018-08-16 Board Of Regents, The University Of Texas System Methods for the detection and treatment of lung cancer

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (en) 1970-11-10 1977-09-15 Organon Nv PROCEDURE FOR DETERMINING AND DETERMINING LOW MOLECULAR COMPOUNDS AND PROTEINS THAT CAN SPECIFICALLY BIND THESE COMPOUNDS AND TEST PACKAGING.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US5006309A (en) 1988-04-22 1991-04-09 Abbott Laboratories Immunoassay device with liquid transfer between wells by washing
US5089424A (en) 1988-06-14 1992-02-18 Abbott Laboratories Method and apparatus for heterogeneous chemiluminescence assay
ES2063353T3 (en) 1989-04-14 1995-01-01 Procedes Petroliers Petrochim HYDROCARBON VAPOCRACHING PROCEDURE.
CA1330545C (en) * 1989-09-15 1994-07-05 Hanna Sikorska Characteristics and use of the anti-cea antibody produced by the hybridoma having the atcc number hbl0029
US20040137538A1 (en) * 2003-01-10 2004-07-15 Bradford Sherry A. Cancer comprehensive assay kit for identifying cancer protein patterns
JP5237108B2 (en) 2005-12-08 2013-07-17 アボット・ラボラトリーズ 9-membered heterobicyclic compounds as protein kinase inhibitors
US9347945B2 (en) * 2005-12-22 2016-05-24 Abbott Molecular Inc. Methods and marker combinations for screening for predisposition to lung cancer
RU2010147643A (en) * 2008-04-23 2012-05-27 Хелтлинкс Лимитед (Au) ANALYSIS FOR GYNECOLOGICAL STATE DETECTION

Also Published As

Publication number Publication date
EP2567232A1 (en) 2013-03-13
CN103038638A (en) 2013-04-10
JP2013525814A (en) 2013-06-20
MX2012012986A (en) 2013-03-05
WO2011140234A1 (en) 2011-11-10

Similar Documents

Publication Publication Date Title
US11193939B2 (en) Method for detecting nucleosome adducts
Sallam Proteomics in cancer biomarkers discovery: challenges and applications
Meding et al. Tissue‐based proteomics reveals FXYD3, S100A11 and GSTM3 as novel markers for regional lymph node metastasis in colon cancer
Zhang et al. Biomarker discovery for ovarian cancer using SELDI-TOF-MS
Kopf et al. Antibody arrays—an emerging tool in cancer proteomics
JP2011523049A (en) Biomarkers for head and neck cancer identification, monitoring and treatment
WO2005094332A3 (en) Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators in non-small cell lung cancer
Hsu et al. Multiplex microsphere‐based flow cytometric platforms for protein analysis and their application in clinical proteomics–from assays to results
Popp et al. Immuno-matrix-assisted laser desorption/ionization assays for quantifying AKT1 and AKT2 in breast and colorectal cancer cell lines and tumors
WO2011047020A1 (en) Multisite biosensor and associated method
Jiang et al. Identification of five serum protein markers for detection of ovarian cancer by antibody arrays
Wellhausen et al. Facing current quantification challenges in protein microarrays
ATE336721T1 (en) HIGH-THROUGHPUT ASSAY TO MEASURE CELLULAR RESPONSES USING MICROARRAYS
WO2021076036A1 (en) Apparatuses and methods for detection of pancreatic cancer
Smith et al. Cancer proteomics and its application to discovery of therapy response markers in human cancer
Zhang et al. A prognostic biomarker for gastric cancer with lymph node metastases
Manole et al. Immunoassay techniques highlighting biomarkers in immunogenetic diseases
WO2007019385A3 (en) Predictive methods for cancer chemotherapy
CA2798441A1 (en) Methods for predicting sensitivity to treatment with a targeted tyrosine kinase inhibitor
Loch et al. Use of high density antibody arrays to validate and discover cancer serum biomarkers
EP2274445A2 (en) Methods and compositions related to quantitative array based methylation analysis
RU2011150291A (en) PHOSPHODYESTERASE-9A AS A MARKER OF A MALIGNANT TUMOR OF THE PROSTATE
Gao et al. Clinical validation of Ki67 by quantitative reverse transcription-polymerase chain reaction (RT-PCR) in HR+/HER2-early breast cancer
Popp et al. Immuno-MALDI (iMALDI) mass spectrometry for the analysis of proteins in signaling pathways
CN113444796B (en) Biomarkers associated with lung cancer and their use in diagnosing cancer

Legal Events

Date Code Title Description
FZDE Dead

Effective date: 20150505